We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Clinical Research on Retinal Neovascularization of Diabetic Retinopathy

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: October 27, 2010
Last Update Posted: October 27, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Tianjin Medical University
Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.

Condition Intervention
The Mechanism of Retinal Neovascularization of Diabetic Retinopathy. Genetic: genetic analyzer

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by Tianjin Medical University:

Arms Assigned Interventions
No Intervention: Lifestyle counseling Genetic: genetic analyzer


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) ≥7.0 mmol/L (≥126 mg/dL), blood glucose ≥11.1 mmol/L (≥200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose ≥11.1 mmol/L (≥200 mg/dL).
  • DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography.
  • All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography.

Exclusion Criteria:

  • Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01229540

China, Tianjin
Tianjin Eye Hospital, Clinical college of Ophthalmology ,Tianjin Medical Univercity
Tianjin, Tianjin, China, 300020
Sponsors and Collaborators
Tianjin Medical University
  More Information

ClinicalTrials.gov Identifier: NCT01229540     History of Changes
Other Study ID Numbers: 08ZCGYSF01700
08ZCGYSF01700 ( Other Identifier: Tianjin Science and Technology Commission )
First Submitted: October 26, 2010
First Posted: October 27, 2010
Last Update Posted: October 27, 2010
Last Verified: September 2008

Additional relevant MeSH terms:
Retinal Diseases
Neovascularization, Pathologic
Retinal Neovascularization
Eye Diseases
Pathologic Processes